Abstract
The latest three-stage development of nanomedicines based on upconversion nanoparticles (UCNPs) in optimizing single treatment (e.g., NIR-triggered drug release, etc.), achieving multimodal synergetic therapy (e.g., chemo-/radiotherapy) and overcoming tumor hypoxia (e.g., disruption of hypoxic tumor, etc.) are discussed by W. Bu and co-workers on page 3987. Such UCNP-based nanomedicines may contribute significantly to promoting the clinic-translational applications of UCNP-based nanomedicines.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
